Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
Profitability
Operating margin-1,774.4%-549pp-1,130.6%-33.1pp-1,618.5%-733pp-1,160.8%-554pp-1,225.8%-659pp
Net margin-1,738.4%-537pp-1,115.3%-43.6pp-1,583.7%-1,145%-1,201.1%
Returns
Return on equity-97.3%+62.1pp-68.5%+53.5pp-64.9%-51.9%-159.3%
Return on invested capital-6,605%
Efficiency
Asset turnover0.0×0.0×0.0×-0.1×-0.1×
Liquidity
Current ratio14×+8.7×12.2×+6.8×10.5×+5.0×12.5×+7.3×5.4×+2.0×
Leverage
Debt-to-equity0.3×-0.8×0.3×-0.6×0.3×-0.4×0.2×-0.3×1.1×0.0×
Per Share
Book value per share$0.58+183%$0.77+170%$0.62+87.0%$0.83+78.5%$0.20-12.2%
Valuation
Market capitalization$1.28B+351%$1.51B+325%$892.04M+119%$619.83M+36.5%$284.95M-50.7%
Price / sales171.9×+132×154.2×+112×141.4×+100×76.5×+41.3×39.4×-1.4×
Price / book6.1×+0.9×6.1×+1.1×4.1×-0.5×2.5×-1.7×5.2×-5.6×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Taysha Gene Therapies, Inc.'s ratios come from?
Every ratio is computed from Taysha Gene Therapies, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.